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ABSTRACT
Vasohibin-1 (VASH1) is an endogenous angiogenesis inhibitor. However, the 
clinical relevance of VASH1 in colon cancer and its regulations on cancer angiogenesis 
and cancer cell biological characteristics are still unknown. Here we showed that 
stromal VASH1 levels were negatively correlated with tumor size, advanced clinical 
stage and distant metastases in colon cancer patients. Overexpression of VASH1 in 
colon cancer cells induced apoptosis and senescence, inhibiting cancer cell growth 
and colony formation in vitro and tumor growth in vivo. In addition, knockdown of 
VASH1 in cancer cells promoted cell growth, adhesion and migration in vitro, and 
enhanced tumorigenesis and metastasis in vivo.
INTRODUCTION
Colorectal cancer (CRC) is a major cause of cancer 
death in the USA and worldwide. There are 100, 000 new 
cases of colon cancer and 50, 000 cases estimated deaths a 
year [1, 2]. Understanding the pathogenesis and regulatory 
processes during cancer development will provide novel 
strategies for colon cancer treatment. In addition to the 
genetically controlled development of tumor cells, tumor 
microenvironmental factors, such as tumor angiogenesis, 
are also critical in enabling tumor growth, progression 
and distant metastasis [3]. Angiogenesis is well defined 
as formation of neovessels and a key event involved in 
tumor oncogenesis. Homeostasis of tumor angiogenesis 
is controlled by a panel of angiogenesis stimulators and 
inhibitors expressed in tumor cells and stroma cells in the 
tumor microenvironment [3-7]. A better understanding of 
biological functions and regulations of those stimulators 
and inhibitors will provide novel targets for the effective 
antiangiogenic therapy against colon cancer and other 
cancers as well. 
Vasohibin family has been recently identified 
as novel negative feedback regulators of angiogenesis 
[6, 8, 9]. There are two members in the vasohibin 
family, vasohibin-1 (VASH1) and its homologue 
vasohibin-2 (VASH2), but they may have distinct roles 
in angiogenesis regulation [10, 11]. VASH1 is selectively 
expressed on the endothelial cells, which is induced by 
angiogenesis stimulators such as vascular endothelial 
growth factor (VEGF) and fibroblast growth factor 2 
(FGF-2) [6, 7]. VASH1 directly regulates endothelial 
cell fate and biological functions resulting in the 
angiogenesis inhibition [12-14]. VASH1 has also been 
confirmed as a critical angiogenesis regulator involved 
in tumor angiogenesis inhibition and prevention of tumor 
growth and metastasis in animal tumor models with 
lung carcinoma and hepatocellular carcinoma [15-18]. 
Importantly, recent studies retrospectively analyzing the 
relationships between clinicopathological features and 
tumor stroma VASH1 expression from cancer patients 
have further indicated that VASH1 is a novel prognosis 
molecular marker in various cancers, including in 
breast cancer [19], renal cell carcinoma [20, 21], lung 
cancer [22], upper urinary tract urothelial carcinoma 
[23], and hepatocellular carcinoma [24, 25]. However, 
little information is known about the role of VASH1 in 
the regulation of tumor angiogenesis, oncogenesis, and 
clinical outcomes of human colorectal cancer. 
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Although VASH1 was originally identified as 
endothelial cell-derived angiogenesis inhibitor, recent 
studies suggested that its expression is not restricted 
to the endothelial cells, but also in other types of cells 
including in cancer cells [18, 26, 27]. However, the 
functional role of VASH1 in directly regulating cancer 
cell biological characteristics is still under investigation. 
Especially, whether cancer cell-derived VASH1 can 
influence tumorigenesis and metastasis has not been fully 
characterized. 
In our current efforts to explore the functional 
role of VASH1 in the pathogenesis of human colon 
cancer, we performed immunohistochemical staining of 
VASH1 in colon cancer tissues and paired paracancerous 
normal tissues from patients with different stages of 
primary colon cancer, and retrospectively analyzed the 
correlations between the cancer stroma VASH1 levels 
with tumor stages, metastases, prognostic factors and 
clinical outcome of patients. Furthermore, we also 
analyzed the VASH1 expression in colon cancer cells 
and determined its regulations on cancer cell fate and 
biological functions. We observed that patients with 
lower stroma VASH1 expression levels had bigger tumor 
sizes, advanced clinical stages, as well as increased 
other organ metastases. Importantly, using the loss-of-
function and gain-of-function strategies, we found that 
VASH1 expression in tumor cells was critical for cell 
growth, adhesion and migration in vitro, and controlled 
tumorigenesis and metastasis in vivo in animal models. 
These data clearly suggest that Vasohibin-1 may function 
as a tumor suppressor in colon cancer that controls both 
cancer angiogenesis and cancer cell biological functions. 
RESULTS
Expression of VASH1 in cancer stroma of colon 
cancer patients
Recent studies suggest that VASH1 is a novel 
angiogenic molecule that is critical for cancer 
angiogenesis and prognosis [19-25]. These novel 
findings prompted us to investigate the functional role 
of VASH1 in the pathogenesis of human colon cancer. 
We first performed immunohistochemical staining to 
detect VASH1 expression in 75 colon cancer tissues and 
59 paracancerous normal tissues from cancer patients 
(Figure 1A & 1B). We found the prevalent expression 
of VASH1 in endothelial cells in both cancer stroma and 
paracancerous normal tissues (Figure 1A). However, in 
the paracancerous normal tissues, the numbers of VASH1+ 
vessels are very low (mean numbers of 3.1), whereas 
significantly increased numbers of VASH1 expression in 
vascular endothelial cells were detected in colon cancer 
stroma (mean numbers of 4.7) (Figure 1B). The result 
strongly suggested the activated angiogenesis in colon 
cancer patients. In addition, we investigated the expression 
levels of the other well-known angiogenic molecules 
CD34 and VEGF-A, as well as lymphoangiogenenic 
molecules D2-40 and VEGF-C in colon cancer tissues 
and paracancerous normal tissues (Figure 1C & 1D). 
CD34 expression was mainly localized in the cytoplasm 
and membrane of the blood endothelial cells, while 
D2-40 expression was observed in the cytoplasm and 
cellular membrane of lymph endothelial cells (Figure 
1C). Furthermore, VEGF-A and VEGF-C were found 
expression in the cytoplasm both in cancer cells and in 
paracancerous normal tissues (Figure 1C). In addition, 
expression levels of CD34, D2-40, VEGF-A and VEGF-C 
in colon cancer tissues were significantly higher than those 
in paracancerous normal tissues (Figure 1D). Our results 
collectively suggest that both active angiogenesis and 
lymphoangiogenesis exist in colon cancer patients, and 
that VASH1 is prevalent in the cancer stroma of cancer 
tissues.
Stroma VASH1 is an important cancer angiogenic 
molecule in human colon cancer 
Given that high density of VASH1 expression in 
blood endothelial cells in cancer stroma, and that active 
angiogenesis and lymphoangiogenesis were observed 
in colon cancer tissues, we next determined whether 
cancer stroma VASH1 is associated with colon cancer 
lymphangiogenesis and angiogenesis. The correlations 
between cancer stroma VASH1 expression level and 
expressions of CD34, D2-40, VEGF-A, VEGF-C in 
cancer tissues were analyzed. We found that cancer stroma 
VASH1 was positively correlated with its expression in 
paracancerous normal tissues (Figure 2A). Furthermore, 
box plot and linear correlation analyses demonstrated that 
there was a significant correlation between stroma VASH1 
and CD34, a key microvessel density (MVD) marker, in 
colon cancer tissues (Figure 2B and 2C). However, there 
were no correlations between cancer stroma VASH1 
expression and VEGF-A expression in cancer cells, and 
lymphoangiogenenic molecules D2-40 (a lymphatic vessel 
density marker) and VEGF-C in cancer tissues (Figure 2D, 
2E and 2F). 
To further investigate the functional effect and 
correlation of VASH1 and CD34 involved in the active 
angiogenesis in colon cancer, we determined whether 
VASH1 expression was co-localized with CD34 in 
endothelial cells in cancer stroma. Immunofluoresence 
double staining with anti-VASH1 and anti-CD34, or 
anti-D2-40 antibodies in the same sections from colon 
cancer tissues was performed. As shown in Figure 2G, 
VASH1-expressing endothelial cells were also co-
expressed with CD34 but not with D2-40 in the same 
vessels in cancer tissues. In addition, serial tissue sections 
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Figure 1: Expression of VASH1 in cancer stroma of colon cancer patients. (A) & (B) Significantly increased VASH1 expression 
density in endothelial cells of blood vessels was detected in colon cancer stroma, compared with that expressed in paracancerous normal 
tissues. Numbers of VASH1+ vessels in 75 colon cancer tissues and 59 paracancerous normal tissues were detected and summarized using the 
immunohistochemical staining. (C) & (D) Expression levels of angiogenic molecules CD34 and VEGF-A, as well as lymphoangiogenenic 
molecules D2-40 and VEGF-C in colon cancer tissues (n=75) and paracancerous normal tissues (n=59) were determined using the 
immunohistochemical staining. Expression level of each dot shown in (B) and (D) is the average numbers (VASH1, CD34 and D2-40) or 
scores (VEGF-A and VEGF-C) per high field (400 x) in each tissue sample. The mean number of each molecule in each group is shown as 
a horizontal line. Significance was determined by unpaired (cancer tissue vs paracancerous tissue) T test.
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Figure 2: Correlations between cancer stroma VASH1 expression and levels of other angiogenic and lymphoangiogenenic 
molecules in colon cancer tissues. (A) Scatter diagram showing a positive correlation between cancer stroma VASH1 and paracancerous 
tissue VASH1. (B) and (C) Scatter diagram (B) and box plot (C) analyses showing positive correlations between expression levels of cancer 
stroma VASH1 and cancer tissue CD34. The mean number of VASH1 in each group is shown as a horizontal line (in C). (D), (E) and (F) 
Scatter diagrams showing that there are no correlations between cancer stromal VASH1 expression and VEGF-A expression in cancer cells 
(D), and lymphoangiogenenic molecules D2-40 (E) and VEGF-C in cancer tissues (F). Expression levels of different molecules in colon 
cancer tissues (n=75) and paracancerous normal tissues (n=59) were immunohistochemically determined as described in Figure 1. (G) 
VASH1-exressing endothelial cells were also co-expressed with CD34, but not with D2-40, in the same blood vessels in cancer tissues. 




with immunohistochemical staining analyses further 
confirmed that VASH1 and CD34 molecules were co-
expressed in blood endothelial cells in colon cancer 
tissues (Supplemental Figure 1A). We then investigated 
the functional role of VASH1 as a critical inhibitor in 
angiogenesis using the in vitro HUVEC tube formation 
assay [28]. Human VASH1 has two isoforms of VASH1-A 
(the major VASH1 isoform) and VASH1-B (the alternative 
splicing isoform)[12]. Both VASH1-A and VASH1-B 
genes were transfected into human umbilical vein 
endothelical cells and their effects on the angiogenenic 
process were evaluated based on the numbers of branch 
points in the formation of endothelial tubules [28, 29]. As 
expected, HUVECs transfected with control vector rapidly 
adhered and formed the endothelial tubules. However, 
expression of VASH1-A and VASH1-B in HUVECs 
significantly attenuated angiogenic tube formation, 
further confirming their inhibitory effect on angiogenesis 
(Supplemental Figure 1B). Notably, this result is different 
from a previous study showing that only VASH1-B can 
inhibit migration and proliferation of endothelial cells 
[12]. Taken together, these data suggest that VASH1 is a 
critical antiangiogenic molecule rather than a marker for 
lymphoangiogenesis in colon cancer patients.
Stroma VASH1 expression level is a significant 
prognostic factor in colon cancer patients
To investigate the clinical significance of VASH1 
in colon cancer, the cancer clinicopathological factors 
of colon cancer patients were retrospectively analyzed 
relative to the stroma VASH1 expression levels. The 
median numbers of VASH1+ vessels in cancer stroma 
of colon cancer samples was used as a cutoff point to 
define the VASH1-high and VASH1-low groups. Fisher 
test was used to analyze the correlations between stroma 
VASH1 and those clinical factors. As shown in Table 1, 
stroma VASH1 expression levels (numbers of VASH1+ 
vessels) were strongly negatively correlated with tumor 
size (p=0.02), advanced clinical stage (p=0.006), and 
increased other organ metastases (p=0.003) in colon 
cancer patients. However, we didn’t find any correlations 
between stroma VASH1 expression levels with other key 
clinicopathological factors, including tumor pathologic 
types, tumor differentiation stages and clinical outcomes 
of RFS and OS, which are different from the recent 
findings from the patients with other types of cancers [19-
25]. Notably, our studies also demonstrated that VASH1 
expression levels in normal paracancerous tissues were 
also negatively correlated with higher tumor sizes (Table 
1). In addition, the correlations between expression levels 
of CD34, VEGF-A, D2-40, and VEGF-C with clinical 
factors were also analyzed. We only found significant 
positive correlations between VEGF-A expression levels 
with advanced clinical stages (p=0.007) and increased 
distant metastases (p=0.004) of colon cancer patients 
(Supplemental Table 1). These results collectively 
suggested that stroma VASH1 is an important negative 
regulatory factor in colon cancer tumorigenesis and 
progression.
Expression of VASH1 in colon cancer cells
In addition to the prevalent expression of VASH1 
in endothelial cells in cancer stroma, recent studies have 
shown that VASH1 can express in cancer cells [24, 30]. 
We thus determined whether VASH1 is also expressed 
in colon cancer cells. As expected, VASH1 expression 
was detected in the cytoplasm of colon cancer cells with 
varied expression densities (Figure 3A). Given that stroma 
VASH1 expression level is a significant prognostic factor 
in colon cancer development, we also retrospectively 
analyzed the correlations of VASH1 expression levels 
in cancer cells with the clinicopathological factors 
of colon cancer patients. Interestingly, we found that 
VASH1 expression levels in colon cancer cells were 
solely positively associated with the distant metastases 
(p=0.016), but were not correlated with the other factors 
or clinical outcomes (Supplemental Table 2), further 
suggesting that VASH1 is important for the dismal 
prognosis of colon cancer. 
To further confirm VASH1 expression in cancer 
cells, we first determined the gene expression levels of 
VASH1-A and VASH1-B in different cancer cell lines, 
including colon, prostate, and breast cancers, using Real-
time PCR analyses [12]. We found that all the tumor 
cell lines expressed both VASH1-A and VASH1-B with 
varied levels (Figure 3B). Among the three colon cancer 
cell lines, HT29 cell line is with lowest expression levels 
for both VASH1A and VASH1-B, while HCT116 cell 
line is with the highest expression for both of the VASH1 
isoforms. VASH1 protein expression levels in different 
tumor cell lines were further confirmed using western blot 
analysis (Figure 3C). In addition, we determined the gene 
expression of VASH2, the other important VASH family 
member, in different cancer cell lines. Recent studies 
have shown that VASH2 also plays a critical role in tumor 
pathogenesis [31]. Our results showed that all the tumor 
cell lines also expressed VASH2 (Supplemental Figure 2). 
However, the VASH2 expression patterns in colon cancer 
cell lines are different from that of VASH1 expression. 
HT29 and SW480 cells were highly expressed VASH2 
compared with that in HCT116 cells. 
VASH1 overexpression in colon cancer cells 
inhibits cancer cell growth, proliferation and 
colony formation 
Given that our studies showed VASH1 expression 
in both primary colon cancer cells and cancer cell 
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lines, and that its intratumoral expression levels were 
associated with tumor metastases, we reasoned that 
VASH1 may directly influence cancer cell growth and 
metastasis capacity. To test these possibilities, we first 
selected HT29 cell line with low VASH1 expression for 
our gain-of-function studies. HT29 cells were transfected 
with VASH1-A or VASH1-B and tumor cell growth and 
proliferation determined using cell growth curve and 
[3H]-thymidine incorporation assays. The expression 
levels of VASH1-A and VASH1-B in HT29 cells after 
transfection were further confirmed by the Realtime-PCR 
analysis (Supplemental Figure 3). As shown in Figure 4A 
and 4B, transfection of both VASH1-A and VASH1-B in 
HT29 tumor cells significantly inhibited cell growth and 
proliferation. In addition, the colony-forming ability of the 
transfected HT29 tumor cells was also investigated. We 
observed that formed colonies of HT29 tumor cells were 
visible after 3 weeks of culture. Furthermore, the numbers 
and sizes of tumor colonies were significantly decreased in 
the HT29 cells transfected with VASH1-A and VASH1-B 
compared with those of control vector-transfected HT29 
cells (Figure 4C). 
We then dissected the potential mechanisms 
responsible for the inhibition of tumor growth and 
proliferation induced by VASH1 expression. Previous 
studies have shown that overexpression of VASH1-B in 
endothelial cells inhibited cell proliferation and DNA 
synthesis, as well as promoted cell apoptosis [12]. We 
reasoned that VASH1-mediated inhibition of HT29 
tumor cells may also be due to the same mechanism as 
Figure 3: Expression of VASH1 in colon cancer cells. (A) VASH1 expression was detected in the cytoplasm of colon cancer cells 
with varied expression densities using the immunohistochemical staining. VASH1 expression levels in cancer cells were classified into 4 
grades according to its intensity: -, no expression; +, low expression with weak intensity; ++, moderate expression with moderate intensity; 
and +++, high expression with strong intensity. (B) Gene expression levels of VASH1-A and VASH1-B in different cancer cell lines, 
including colon cancer (HT29, HCT116 and SW480), prostate cancer (PC3), and breast cancer (MCF7), using Real-time PCR analyses. 
mRNA levels in each cancer cell line were normalized to the relative quantity of GAPDH expression, and then further compared to the 
expression level in HT29 cells (set as 1). Results shown in the histogram are mean ± SD from three independent experiments. (C) Protein 
expression levels of VASH1 in different cancer cell lines were determined using western blot analyses. GAPDH expression in cancer cell 
lysates was included as a control. 
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Figure 4: Overexpression of VASH1 in colon cancer HT29 cells significantly inhibits cancer cell growth, proliferation 
and colony formation. (A) and (B) Transfection of both VASH1-A and VASH1-B in HT29 tumor cells significantly inhibited cell 
growth and proliferation. HT29 cells transfected with vector served as a negative control. Transfected HT29 cells were cultured at a started 
number of 3 × 105/well in 6-well plates, or 5 × 103/well in 96-well plates. The cell growth was evaluated at different time points using cell 
number counting (in A), and cell proliferation was determined using [3H]-thymidine assays (in B). (C) Transfection of both VASH1-A and 
VASH1-B dramatically decreased the numbers and sizes of tumor colonies in HT29 cells after 3 weeks of culture. Two hundred to five 
hundred per well of HT29 cells transfected with VASH1-A & B or control vector were seeded in 6-well plates and cell colonies counted 
after 3-4 weeks of culture. Results shown in the histogram are mean ± SD from three independent experiments. (D) and (E) VASH1-
mediated inhibition of HT29 cell growth and proliferation was due to the induction of cell apoptosis and senescence. Significantly increased 
apoptotic cell populations were induced in HT29 cells after transfection with VASH1-B (in D). However, transfection with VASH1-A, but 
not VASH1-B in HT29 cells markedly induced SA-β-Gal positive cell populations in HT29 tumor cells (in E). Transfected HT29 tumor 
cells were cultured for additional 72 hours. Apoptosis in transfected tumor cells was analyzed after staining with PE-labeled Annexin V and 
7-AAD (in D). Senescent cells were analyzed using the SA-β-Gal activity assay and the SA-β-Gal positive cells were identified with dark 
blue granules as indicated by the arrows (in E). Data in (A) to (E) are mean ± SD from three independent experiments with similar results. 
*p<0.05 and **p<0.01 compared with the vector control group.
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in endothelial cells. Apoptosis of HT29 tumor cells was 
analyzed at 48 hours post-transfection with VASH1-A 
and VASH1-B, using the 7-AAD and Annexin-V staining 
analyses. We observed significantly increased apoptotic 
cell populations in HT29 cells after transfection with 
VASH1-B (Figure 4D). Furthermore, transfection with 
VASH1-A also induced moderate levers of apoptosis in 
HT29 cells. Since senescent human cells have permanent 
growth arrest [32], we therefore determined whether 
senescence induction mechanism was also involved in 
the suppressed cell growth and proliferation mediated 
by overexpression of VASH1 in tumor cells. In addition 
to cell cycle arrest and morphologic characteristics, SA-
β-Gal is the first biomarker used to identify senescent 
human cells [33-35]. As shown in Figure 4E, we found 
significantly increased SA-β-Gal positive cell populations 
in HT29 tumor cells after transfection with VASH1-A, 
indicating the induction of tumor cell senescence. In 
contrast, HT29 tumor cells transfected with VASH1-B 
and control vector did not induce SA-β-Gal expression. 
Our results collectively suggested that overexpression 
of VASH1 in colon cancer cells can induce both cell 
apoptosis and senescence, resulting in the inhibition of 
cancer cell growth and colony formation. 
VASH1 knockdown in colon cancer cells promotes 
cancer cell growth, adhesion and migration 
To further confirm the functional role of VASH1 
in regulating colon cancer cell growth, we also utilized 
the loss-of-function strategy to knockdown VASH1 gene 
with shRNA in VASH1 highly expressed HCT116 tumor 
cells and then determined its effect on tumor growth 
and proliferation. We selected a shRNA which can 
specifically target both VASH1-A and VASH1-B isoforms 
(Supplemental Figure 4A). The knockdown efficiency on 
VASH1 expression by the shRNA was further confirmed in 
both VASH1-transfected 293T cells and in HCT116 tumor 
cells, using western-blot and Real-time PCR analyses, 
respectively (Supplemental Figure 4B and 4C, and 
Figure 5A). As expected, silence of VASH1 expression in 
HCT116 tumor cells dramatically promoted tumor growth 
and increased cell proliferation (Figure 5B and 5C). 
Furthermore, the numbers and sizes of tumor cell colonies 
were also significantly increased in HCT116 cells after 
knockdown of VASH1 gene in a colony formation assay 
(Figure 5D). These results further suggested that VASH1 
expression in colon cancer cells directly controlled cell 
growth and fate. 
In addition to the tumor growth and colony 
formation, we next investigated whether VASH1 
expression in tumor cells is critical for the capacity of cell 
adhesion and migration. We observed that knockdown 
of VASH1 in HCT116 tumor cells markedly increased 
the adherent ability of tumor cells in the fibronection-
coated plates (Figure 5E). Furthermore, knockdown of 
VASH1 in HCT116 tumor cells significantly promoted 
the migration of tumor cells compared with the control 
shRNA-transfected tumor cells in a transwell migration 
assay (Figure 5F). The transmigration result was further 
confirmed in VASH1 shRNA-transfected HCT116 tumor 
cells using the wound closure assays (Figure 5G). These 
data collectively indicate that VASH1 in tumor cells 
is important for the regulation of tumor cell functions, 
including adhesion, migration and metastasis. 
VASH1 expression in tumor cells controls 
tumorigenesis and metastasis in vivo
These in vitro studies provided us important 
information regarding the importance of VASH1 in 
controlling colon cancer tumor cell growth and metastasis. 
We next performed complementary in vivo studies, using 
human colon cancer cells in humanized nude and Rag1-
/- immunodeficient mouse models, and explored whether 
VASH1 is critical for the tumorigenesis and metastasis 
of colon cancer in vivo [36, 37]. We first performed 
xenograft models to investigate whether overexpression of 
VASH1 in colon cancer cells can inhibit tumor growth and 
tumorigenesis. Human colon cancer HT29 cells transfected 
with VASH1-A, VASH1-B or control vector, were 
subcutaneously injected into nude mice. Tumor growth 
was evaluated. At the end of experiments, tumors were 
isolated from different groups of the sacrificed mice and 
weighted. HT29 tumor cells transfected with control vector 
grew progressively in nude mice. However, transfection 
of VASH1-A or VASH1-B in HT29 cells dramatically 
inhibited tumor growth (Figure 6A). Furthermore, 
tumor sizes collected from the VASH1-A or VASH1-B 
transfected HT29 groups on day 24 post inoculation were 
much smaller than those in the control vector-transfected 
group (Figure 6B). In addition, the average tumor weights 
obtained from the VASH1-A- and VASH1-B-transfected 
groups also showed much lower than that of control vector 
group (Figure 6C). Besides the tumor growth, we also 
verified the effects of VASH1 overexpression on tumor 
cell proliferation, apoptosis, senescence, and angiogenesis 
in tumor tissues. A large numbers of Ki-67+ cells were 
observed in HT29 tumor cells transfected with control 
vector. In contrast, transfection of VASH1-A or VASH1-B 
in HT29 cells significantly decreased Ki-67+ cell 
populations in the tumor tissues (Figure 6D and 6E). In 
addition, consistent to our in vitro observations (Figure 4), 
transfection of VASH1-A significantly induced tumor cell 
senescence evidencing by the increased SA-β-Gal positive 
cell populations (Figure 6F and 6G); and transfection of 
VASH1-B markedly increased the apoptotic cells (cleaved 
caspase 3+ cells) in the tumor tissues (Figure 6H and 
6I). However, we did not find significantly inhibitory 
effects on tumor angiogenesis mediated by VASH1-A & 
B overexpression in tumor cells based on CD34+ blood 
vessel analyses in vessels in tumor tissues (Supplemental 
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Figure 5: Knockdown of VASH1 in colon cancer HCT116 cells promotes cancer cell growth, adhesion and migration. 
(A) The knockdown efficiency on VASH1-A and VASH1-B expression by the shRNA was determined in HCT116 tumor cells using Real-
time PCR analyses. mRNA levels in each group were normalized to the relative quantity of GAPDH expression and compared against 
VASH1 expression level in control scramble shRNA group (set as 1). Results shown are mean ± SD from three independent experiments. 
**p<0.01 compared with the control scramble shRNA group. (B) and (C) Knockdown of VASH1 expression in HCT116 tumor cells 
dramatically promoted tumor cell growth and proliferation. HCT116 cells transfected with control shRNA served as a negative control. The 
cell growth of transfected HCT116 cells was evaluated at different time points using cell number counting (in B), and cell proliferation was 
determined using [3H]-thymidine assays (in C). **p<0.01 compared with the control scramble shRNA group. (D) Knockdown of VASH1 
expression in HCT116 cells dramatically decreased the numbers and sizes of tumor colonies in colony formation assays. Results shown 
in the histogram are mean ± SD from three independent experiments. **p<0.01 compared with the control shRNA group. (E) Knockdown 
of VASH1 gene in HCT116 tumor cells markedly increased the adherent ability of tumor cells. The adhesion of transfected colon cancer 
cells was cultured in the fibronection-coated plates for 45 minutes. Adherent cells were counted and averaged in 10 fields at high (× 400) 
magnification with a microscope. **p<0.01 compared with the control shRNA group. (F) and (G) knockdown of VASH1 gene in HCT116 
tumor cells significantly promoted the migration of tumor cells compared with the control shRNA-transfected tumor cells in the transwell 
migration assays (in F) and the wound closure assays (in G). *p<0.05 and **p<0.01 compared with the control shRNA group. Data in (A) 
to (G) are from three independent experiments with similar results.
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Figure 6: Overexpression of VASH1 in human colon cancer HT29 cells inhibited tumor growth and tumorigenesis in 
vivo. (A) Overexpression of VASH1-A and VASH1-B in HT29 cells dramatically inhibited tumor growth in nude mice. (B) Representative 
image of the xenograft tumors shown are obtained from the 3 groups at the endpoint of the experiments (day 24). (C) The mean weights 
of xenograft tumors obtained from the 3 groups at the endpoint of the experiments (day 24). Human colon cancer HT29 cells (5 × 106/
mouse) transfected with VASH1-A, VASH1-B or control vector, were subcutaneously injected into nude mice (n=5). Tumor growth was 
evaluated (in A). At the end of experiments, tumors were isolated from the sacrificed mice and weighted (B). **p<0.01 compared with the 
control vector group (in B). (D) & (E) Transfection of VASH1-A or VASH1-B in HT29 cells significantly decreased Ki-67+ cell populations 
compared with vector-transfected group in the tumor tissues. Representative pictures for the expression of Ki-67 in tumor tissue sections 
determined using the immunohistochemical staining (in D). **p<0.01 compared with the control vector group. (F) & (G) Transfection of 
VASH1-A significantly increased SA-β-Gal positive cell populations in the tumor tissues. Representative pictures for the expression of 
SA-β-gal in tumor tissue sections determined using the SA-β-gal staining. **p<0.01 compared with the control vector group. (H) & (I) 
Transfection of VASH1-A and VASH1-B markedly increased Cleaved-Caspase 3+ cells in the tumor tissues. Representative pictures for 
the expression of Cleaved-Caspase 3 in tumor tissue sections determined using the immunohistochemical staining. #p<0.05 and **p<0.01 
compared with the control vector group. Results shown in (C), (E), (G) and (I) are mean ± SD from 5 mice per group. 
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Figure 5). These results clearly suggest that VASH1 
overexpression in colon cancer cells directly suppresses 
tumor growth and tumorigenesis, resulting from the 
induction of tumor cell apoptosis and senescence.
We also performed a parallel xenograft model 
to investigate whether knockdown of VASH1 in colon 
cancer cells can promote tumor growth and tumorigenesis. 
Human colon cancer HCT116 cells transfected with 
VASH1 shRNA or control shRNA, were subcutaneously 
injected into Rag1-/- mice. As shown in Figure 7A, 
knockdown of VASH1 in HCT116 cells dramatically 
promoted tumor growth, compared with the control 
shRNA–transfected HCT116 cells. In addition, tumor 
sizes collected from the VASH1 shRNA group on day 33 
post inoculation were significantly larger than those in the 
control shRNA group (Figure 7B). Notably, the average 
tumor weights obtained from the VASH1 shRNA group 
also showed much higher than that of control shRNA 
group (Figure 7C). In addition, knockdown of VASH1 
expression in HCT116 cells significantly increased Ki-67+ 
cell populations in the tumor tissues (Figure 7D). These 
data indicated that silence of VASH1 expression in tumor 
cells directly enhanced tumor growth and tumorigenesis 
in vivo. 
We next investigated whether knockdown of 
VASH1 gene promoted tumor metastasis using our 
previously established adoptive transfer tumor models 
[36, 37]. Human colon cancer HCT116 cells transfected 
with VASH1-specific or control shRNA were injected 
tail intravenously into Rag1-/- mice. Livers and lungs 
were harvested from the mice of different groups at 6 
weeks post injection, and tumor metastases determined. 
As expected, knockdown of VASH1 in HCT116 cells 
dramatically increased tumor macrometastatic numbers 
both in lung and in liver surfaces (Figure 7E). These results 
are consistent with our findings in clinical association 
analyses in patient samples showing that VASH1 
expression in stroma and cancer cells are highly related 
to the other organ metastases (Table 1 and Supplemental 
Table 2). Furthermore, we confirmed, using the H & E 
staining on sections from embedded liver and lung tissues, 
that high amount of tumor cells infiltrated into livers and 
lungs obtained from VASH1 shRNA treatment group, 
but not from the control shRNA treatment group (Figure 
7F). Our studies collectively demonstrate that VASH1 is 
a tumor suppressor and plays a critical role in directing 
tumorigenesis and metastasis. 
DISCUSSION
Improved understanding of the molecular processes 
and regulations of tumor angiogenesis and oncogenesis 
will provide novel strategies for colon cancer treatment. 
Our current studies have identified that VASH1 functions 
as a significant tumor suppressor in human colon cancer. 
Based on the clinical sample analyses, we demonstrated 
that colon cancer stroma VASH1 is critical for cancer 
angiogenesis and its levels are strongly negatively 
correlated with tumor size, advanced clinical stage, and 
other organ metastases. Furthermore, cancer cell-derived 
VASH1 can directly regulate cell growth, adhesion and 
migration in vitro, as well as control tumorigenesis and 
metastasis in vivo. Our studies indicate that VASH1 could 
be not only a useful prognosis biomarker but also a novel 
therapeutic target for human colon cancer. 
Tumor angiogenesis is a universal feature and also 
a key process for all cancers. VASH1 has been identified 
as a novel inhibitor involved in angiogenesis regulation 
[6-9]. Furthermore, VASH1 has also been found in 
cancer pathological conditions as a critical angiogenesis 
regulator involved in the tumor angiogenesis inhibition 
and prevention of tumor growth and metastasis in 
animal tumor models [15-18]. Based on the clinical 
sample analyses, our results strongly suggest that active 
angiogenesis and lymphoangiogenesis exist in colon 
cancer patients evidencing by the high expression levels 
of angiogenic molecules CD34 and VEGF-A, as well 
as lymphoangiogenenic molecules D2-40 and VEGF-C 
in colon cancer tissues [3, 5, 38-45]. We also confirmed 
that prevalent expression of VASH1 in endothelial cells 
in colon cancer stroma and paracancerous normal tissues, 
further suggesting the dynamic balance and regulation 
between angiogenic and antiangiogenic actions within 
the colon cancer tumor microenvironment. The major 
inducers for VASH1 expression in stroma endothelial cells 
are angiogenesis stimulators including VEGF-A [6, 7, 38]. 
Interestingly, we didn’t observed a correlation between 
the cancer stroma VASH1 expression and cancer cell 
VEGF-A in colon cancer patients. However, significant 
correlation and co-expression between stromal VASH1 
and microvessel density marker CD34 were found in 
colon cancer tissues. In addition, the in vitro HUVEC tube 
formation assay further indicated that both VASH1-A and 
VASH1-B genes could inhibit the angiogenenic process 
and the formation of endothelial tubules. These results 
indicated that VASH1 is an important cancer angiogenic 
molecule involved in the colon cancer antiangiogenesis. 
Several recent studies have suggested that VASH1 
could be a significant prognostic marker in various types 
of cancers [19-25]. In the current study, we retrospectively 
analyzed the correlations of stroma VASH1 expression 
levels with the cancer clinicopathological factors of colon 
cancer patients. Our studies demonstrated that stroma 
VASH1 expression levels were strongly negatively 
correlated with tumor size, advanced clinical stage, 
and other organ metastases in colon cancer patients. 
However, we didn’t find correlations between stroma 
VASH1 expression levels with clinical outcomes of 
RFS and OS in colon cancer patients. Interestingly, our 
results are different from recent reports showing that 
VASH1 expression has significant positive correlation 
with pathological TNM stage, tumor stromal invasion, 
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Figure 7: Knockdown of VASH1 in human colon cancer HCT116 cells promoted tumor tumorigenesis and metastasis in 
vivo. (A) Knockdown of VASH1 in HCT116 cells dramatically promoted tumor growth in Rag1-/- immunodeficient mice. (B) Representative 
image of the xenograft tumors shown are obtained from the two groups at the endpoint of the experiments (day 33). (C) The mean weights 
of xenograft tumors obtained from the two groups at the endpoint of the experiments (day 33). Human colon cancer HCT116 cells (4 × 
106/mouse) transfected with VASH1 shRNA or control shRNA, were subcutaneously injected into Rag1-/- mice (n=5). Tumor growth was 
evaluated (in F). At the end of experiments, tumors were isolated from the sacrificed mice and weighted (G). *p<0.05 compared with the 
control shRNA group (G). (D) Knockdown of VASH1 in HCT116 cells significantly increased Ki-67+ cell populations compared with 
control shRNA group in the tumor tissues. Tumor tissue sections were determined for Ki-67 expression using the immunohistochemical 
staining. Results shown are mean ± SD from 5 mice per group. **p<0.01 compared with the control shRNA group. (E) Knockdown of 
VASH1 in HCT116 cells dramatically increased tumor macrometastatic numbers in lung and liver surfaces. Human colon cancer HCT116 
cells (2 × 106/mouse) transfected with VASH1-specific or control shRNA were injected tail intravenously into Rag1-/- mice. Livers and lungs 
were harvested from the mice of different groups at 6 weeks post injection, and tumor metastases determined. Results shown are mean ± 
SD from 5 mice per group. **p<0.01 compared with the control shRNA group. (F) H & E staining on sections from embedded lung and 
liver tissues showed that high amount of tumor cells infiltrated into lungs and livers obtained from VASH1 shRNA treatment group, but not 
from the control shRNA treatment group. Tumor metastatic spots were indicated by the arrows.
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lymph node status and distant metastasis, and negative 
correlation with OS and RFS in colon cancer [27, 46]. 
In their studies, they provided mixed information and 
did not separate the analyses of clinical relevance with 
VASH1 expression in tumor cells or in endothelial cells. 
In addition, the difference between these two studies might 
be due to the small sample size and very limited follow-
up information from cancer patients in our current study. 
Therefore, our future efforts should expand the colon 
cancer sample size to further confirm the functional role 
of VASH1 in the angiogenesis regulation and pathogenesis 
of colon cancer. Furthermore, it remains unclear how 
VASH1 performs antiangiogenic actions in colon cancer 
in vivo. Mechanistic studies using suitable animal models 
are needed to firmly establish the role of VASH1 in human 
colon cancer development. 
VASH1 expression has been found in cancer cells 
including in colon cancer, but the mechanisms responsible 
for the regulation of cancer cell growth and biological 
characteristics or functions are unclear [18, 26, 27]. In 
addition, recent studies using recombinant adenovirus 
encoding VASH1 have shown that VASH1 inhibited tumor 
growth and metastasis in vivo [15, 16]. However, these 
studies only focused on how the administration of VASH1 
regulated tumor angiogenesis and lymphangiogenesis, 
but didn’t characterize the direct effects on tumor cells 
induced by VASH1 administration. In our current studies, 
we observed that VASH1 endogenously expressed both in 
primary cancer cells from colon cancer patients as well 
as in colon cancer cell lines. We further utilized the gain-
of-function and loss-of-function strategies and discovered 
that cancer cell-derived VASH1 can directly control tumor 
cell fate and biological functions through the following 
actions. First, both VASH1-A and VASH1-B expression 
directly inhibit tumor cell growth and proliferation. 
Notably, the mechanisms responsible for VASH1-A and 
VASH1-B mediated tumor cell inhibition are different. 
We observed that VASH1-A expression in tumor cells 
significantly induced cell senescence [34, 35]. However, 
expression of VASH1-B dramatically induced apoptosis 
in colon cancer cells. These results are consistent 
with the findings in the endothelial cells showing that 
overexpression of VASH1-B inhibited DNA synthesis and 
induced apoptosis of endothelial cells [12]. In addition, 
VASH1 expression is critical for regulating cancer cell 
key biological functions, such as colony formation, 
adhesion and migration. Finally, VASH1 expression can 
control tumorigenesis and metastasis in vivo in human 
colon cancer models. Interestingly, our studies about 
the effect of VASH1-A on tumor cells are different from 
the observations in endothelial cells from other groups, 
showing that overexpression of VASH1-A does not affect 
endothelial cell growth and migration, but enhances 
cell ability for stress resistance to premature senescence 
and cell death [12, 14]. The difference may suggest that 
VASH1 has distinct functional roles varied among the cell 
types. In support of our assertion, a previous study has 
shown that overexpression of VASH1-A and B induced 
apoptosis in proliferating human fibroblasts, but did 
not affect cell growth of keratinocytes [12]. Notably, 
our retrospective analysis results showed that VASH1 
expression levels in colon cancer cells were solely 
positively associated with the distant metastases, which 
is opposite to the results obtained from our in vitro and 
in vivo studies. The possibility may exist that VASH1 
expressing in tumor cells is nonfunctional because of the 
mutation or methylation. In support of our prediction, a 
more recent study has suggested that enhancer of zeste 
homologue 2 (EZH2), a member of the polycomb group 
of genes (PcG), is overexpressed in human cancer tissues 
and can directly induce VASH1 methylation and promote 
tumor angiogenesis [4]. Furthermore, VASH1 mutations 
have been observed in colon, rectal and lung cancers 
[47-49]. Taken together, our studies identify that VASH1 
functions as a significant tumor suppressor in human colon 
cancer that not only can inhibit cancer angiogenesis but 
also direct control cancer cell fate and biological functions. 
These studies could provide new insights relevant to the 
development of novel strategies using VASH1 as a useful 
target for human colon cancer treatment. 
MATERIALS AND METHODS
Human samples and cell lines
Tumor samples of paraffin-embedded tissue sections 
and clinicopathological features were obtained from 75 
colon cancer patients at Jinan Central Hospital affiliated 
to Shandong University from 2005 to 2008, who have 
undergone surgery and given informed consents for 
enrollment in a prospective tumor procurement protocol 
approved by the Shandong University Institutional Review 
Board. None of the patients had received any preoperative 
chemotherapy or irradiation before the operation.
Different types of tumor cell lines (breast, prostate 
and colon cancers), human umbilical vein endothelial cell 
(HUVEC) line, and HEK 293T cells were either purchased 
from the American Type Culture Collection (ATCC, 
Manassas, VA) or established in our laboratory. Human 
colon cancer cell lines SW480, HCT 29 and HCT116, as 
well as HEK 293T were maintained in DMEM medium 
containing 10% fetal calf serum (FCS). Other tumor cell 
lines PC3 and MCF7 were maintained in RPMI 1640 
medium containing 10% FCS. 
Immunohistochemical staining and quantification 
method
The expression of VASH1, VEGF-A, CD34, 
VEGF-C and D2-40 (Podoplanin) in paraffin-embedded 
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colon cancer tissue sections were determined using 
immunohistochemical staining with the following primary 
anti-human monoclonal antibodies: anti-VASH1(clone 
4A3, Abnova Corporation, Taiwan, China), anti-VEGF-A 
(sc-152, Santa Cruz Biotechnology), anti-CD34 (ZA-0550, 
Zhongshan Jinqiao Co., Beijing, China), anti-VEGF-C 
(ZA-0266, Zhongshan Jinqiao Co) and anti-D2-40 
(DAKO, Carpinteria, CA, USA), at diluted concentrations 
of 1: 1000, 1: 50, 1: 50, 1:100 and 1:200, respectively. The 
sections were stained for overnight at 4°C with primary 
antibodies and stained for 30 min at room temperature 
with secondary antibodies. Controls were performed by 
incubating slides with the isotype control antibody instead 
of primary antibodies, or a second antibody alone. The 
positive cells were counted and analyzed microscopically.
The stained sections were evaluated manually using 
a computerized image system composed of a Leica ICC50 
camera system equipped on a Leica DM750 microscope 
(North Central Instruments, Minneapolis, MN). 
Photographs were obtained from 20 randomly selected 
areas within the tumor tissues of 10 cancer nest areas and 
10 cancer stroma areas at a high-power magnification 
(400 ×). To analyze VASH1, CD34 and D2-40 expression 
in endothelial cells, ten fields (400 ×, magnification) of 
each tumor tissue section, including both cancer nest and 
stroma areas were counted, and the means of positive 
vessel numbers per field summed and reported. VASH1-
positive vessels were counted in the “hot spot” that the 
highest number of the positive vessels for anti-CD34 was 
identified. VASH-1, VEGF-C and VEGF-A expression in 
tumor cells were evaluated semi-quantitatively based on 
immunostaining intensity and area extent. Each slide was 
given a score according to the intensity of cytoplasmic 
staining (0, negative; 1, weak; 2, moderate; 3, strong). The 
counting was performed by 2 independent investigators 
(S. Liu and B. Han) who had no previous knowledge of 
the patient clinical backgrounds, and the results were 
averaged.
Indirect immunofluorescence staining
For indirect immunofluorescence staining of 
VASH1, CD34, and D2-40 in colon cancer tissues, 
paraffin-embedded sections were incubated with a 
mixture of mouse anti-human VASH1 (clone 4A3, Abnova 
Corporation, Taiwan, China) and rabbit anti-CD34 (ZA-
0550, Zhongshanjinqiao, China), or rabbit anti-D2-40 
(Cell Signaling Technology) primary antibodies. The 
sections were then incubated with a mixture of two 
secondary antibodies [Alexa Fluor 488–conjugated goat 
anti-rabbit IgG (H+L) and Alexa Fluor 594–conjugated 
goat anti-mouse IgG (H+L) (Proteintech Group, Inc, 
China)]. Specimens were then counterstained with 
4’-6-Diamidino-2-phenylindole (DAPI) (Invitrogen). 
Gene constructs and cell transfection
The human VASH1A-p3xFLAG CMS-14 and 
VASH1B-p3xFLAG CMS-14 were generously gifted 
from Dr. Gerold Untergasser at the Innsbruck Medical 
University, Austria [12]. Human VASH-1 shRNA construct 
in pLKO.1-puro vector (NM_014909.2-1061s1c1) was 
purchased from Sigma. Scramble coding cDNA sequence 
for VASH1 shRNA was constructed with pLKO.1-
puro vector and used as a control shRNA. Transfection 
of those constructs in tumor cells was performed using 
Lipofectamine 2000 (invitrogen) according to the 
manufacturer’s instructions.
HUVEC tube formation assay
Angiogenesis activity mediated by VASH1 
expression was analyzed based on the human umbilical 
vein endothelial cell (HUVEC) tube formation assay, as 
previously described [28]. Briefly, HUVECs cultured in 
EGM with 5% fetal bovine serum and 1% endothelial 
cell growth supplement (ECGS) were transfected with 
VASH1-A, VASH1-B, or control vector. Transfected 
HUVECs were seeded at 2.5 × 104 cells/ well into 
matrigel-coated 48-well plates (BD Biosciences). The 
tube formation was observed after 6 hours of culture 
using an inverted phase contrast microscope and imaged 
by a Nikon digital camera, and then was quantified and 
summed by counting the numbers of branch points at a 
high-power magnification (200 ×). 
Reverse-transcription PCR analysis
Total RNA was extracted from tumor cells using 
Trizol reagent (Invitrogen), and cDNA was transcribed 
using a SuperScript II RT kit (Invitrogen), both according 
to manufacturers’ instructions. 
VASH1-A, VASH1-B and VASH2 mRNA 
expression levels were determined by reverse-
transcription PCR using specific primers with the SYBR 
Green PCR Master Mix (Biosystems), and mRNA 
levels in each sample were normalized to the relative 
quantity of Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) as previously described [36, 37]. The 
specific primers used are listed as follows: VASH1-A, 
F: 5’-CAAAGAGGCCCTGCCAATCA-3’ and R: 
5’-TGGCGGAAGTAGTTCCCTGA-3’; VASH1-B, 
F: 5’-GACCTCTGACAGGGCTGATG-3’ and R: 
5’-TCAACCTACCCCACCCTCAC-3’; and VASH2, 
F: 5’-GCTGGTCCTCAACGTCTCAA -3’ and R: 
5’-CTGGGGGACAGGGATTTTCC-3’. 
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Cell growth and functional proliferation assay
Colon cancer cell lines transfected with or without 
plasmids VASH1-p3xFLAG, VASH1 shRNA, or related 
controls, were cultured at a started number of 3 × 105/well 
in 6-well plates. The cell growth was evaluated at different 
time points using cell number counting. In addition, cell 
proliferation of those transfected cells was determined 
using [3H]-thymidine assays as we previously described 
[36, 37]. In brief, different numbers of transfected tumor 
cells (5 × 103, 1 × 104 or 2 × 104) were cultured in 96-
well plates in cell assay medium containing 2% FCS. After 
56 hours of culture, [3H]-thymidine was added at a final 
concentration of 1 μCi/well, followed by an additional 16 
hours of culture. The incorporation of [3H]-thymidine was 
measured with a liquid scintillation counter.
Western-blotting analysis
293T cells were transfected with VASH1A-
p3xFLAG or VASH1B-p3xFLAG, combined with or 
without VASH1 shRNA, or scramble control shRNA for 
48 hours. Transfected 293T cells were purified and then 
the lysates prepared for western blot analyses. An anti-
Flag Monoclonal antibody (Clone M2, Sigma) was used in 
the western-blotting assays. To determine VASH1 protein 
expression in tumor cells, the lysates from different types 
of tumor cell lines were prepared for western blot analyses 
using an anti-VASH1 antibody (clone 4A3, Abnova 
Corporation). 
Cell apoptosis assay and senescence associated 
β-Galactosidase (SA−β-Gal) staining
Colon cancer cells transfected with VASH1-A, 
VASH1-B, or control vector were cultured for 72 hours. 
Apoptosis in transfected tumor cells were analyzed 
after staining with PE-labeled Annexin V and 7-AAD 
(BD Biosciences, San Diego, CA). All the stained cells 
were analyzed on a FACSCalibur (BD Bioscience) and 
the data were analyzed with FlowJo software (Tree Star, 
Ashland, OR). Furthermore, SA-β-Gal activity in tumor 
cells was detected as we previously described [34, 35]. 
Briefly, transfected tumor cells were cultured for 3 or 5 
days and then were washed in PBS (pH 7.2), fixed in 3% 
formaldehyde, and followed to incubate overnight at 37°C 
with freshly prepared SA-β-Gal staining solution (1 mg/
ml X-gal, 5 mM K3Fe[CN]6, 5 mM K4Fe[CN]6, 2 mM 
MgCl2 in PBS at pH 6.0). The stained cells were washed 
with H2O and examined SA-β-Gal expression with a 
microscope. 
Colony formation assay
Two hundred to five hundred per well of tumor cells 
transfected with VASH1-A & B, VASH1 specific shRNA, 
control vector or scramble shRNA, were seeded in 6-well 
plates for culture. Cell colonies were stained with Gimsa 
and counted after 3-4 weeks of culture. 
Wound closure and migration assays
HCT116 tumor cells were transfected with VASH1 
shRNA or control shRNA. After 24 hours of transfection, 
the cells were wounded with a pipette tip across the cell 
monolayer. The scratches were photographed with a 
digital camera after additional 24 and 48 hours of culture. 
The closure was estimated as the wounded area relative to 
the initial area. For migration assays, 1 × 105 transfected 
HCT116 tumor cells were put in the up-chambers with 
serum-free medium in the transwell assays (8 µm insert). 
The migrated cells in the lower chambers were collected 
and cell numbers counted after 12 hours of culture. 
Adhesion assay
The adhesion of transfected colon cancer cells was 
determined as previously described [50]. Flat bottom 96-
well plates were coated with 50 μl per well of fibronectin 
(10 µg/ml, BD Biosciences) overnight at 4 °C and blocked 
with 2% BSA in PBS at 37 °C for 2h. The transfected 
tumor cells (2 × 105/ml) suspended with basic medium 
without FBS and 10μl cells were seeded into each well 
and incubated for 45 minutes at 37 °C. After washing three 
times with PBS to remove non-adherent cells, the cells 
attached on the plates were fixed with 4% formaldehyde 
for 4 minutes and stained with 0.03% crystal violet 15 
minutes. Adherent cells were counted and averaged in 10 
fields at high (× 400) magnification with a microscope.
In vivo tumorigenesis and metastasis studies
Rag1-/- immunodeficient and nude mice (6-8 weeks) 
were purchased from The Jackson Laboratory (USA) and 
Laboratory Animal Center of the Academy of Military 
Medical Science (Beijing, China), respectively, and 
maintained in the institutional animal facility. All animal 
studies have been approved by the Institutional Animal 
Care Committee. For tumorigenesis studies, human 
colon cancer HT29 cells (5 × 106/mouse) transfected 
with VASH1-A, VASH1-B or control vector, were 
subcutaneously injected into nude mice. In a parallel 
experiment, human colon cancer HCT116 cells (4 × 
106/mouse) transfected with VASH1 shRNA or control 
shRNA, were subcutaneously injected into Rag1-/- mice. 
Five mice were included in each group. Tumor size was 
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measured with calipers every 2-3 days. Tumor volume 
was calculated on the basis of the formula 1/2 (length2 × 
width). At the end of experiments, the mice were sacrificed 
and tumors were isolated and weighted. For evaluation 
of tumor cell proliferation, apoptosis, senescence, and 
angiogenesis in tissues, tumor tissues were prepared for 
paraffin-embedded sections (4~8 µm), and determined 
using the immunohistochemical staining or SA-β-gal 
staining, as described above. The primary antibodies 
include: anti-Ki-67 (Cell Signaling Technology), anti-
cleaved Caspase-3 (#9664, Cell Signaling Technology), 
and anti-CD34 (ab81289, Abcam), at diluted 
concentrations of 1:50, 1:1000, and 1:200, respectively.
 For tumor metastasis studies, transfected human 
colon cancer HCT116 cells (2 × 106/mouse) were injected 
tail intravenously into Rag1-/- mice. Five mice were 
included in each group. The mice were sacrificed and 
livers and lungs were harvested at 6 weeks post injection. 
Visible lung and liver surface macrometastatic white 
spots were counted using a dissecting microscope. For 
tissue morphology and metastasis evaluation, liver and 
lung tissues were embedded into OCT and prepared for 
cryostat sections (4~8 µm). Hematoxylin and eosin (H & 
E) staining were performed with sections from embedded 
samples.
Statistical analysis
For human clinical sample analyses (in tables), 
given that there was no clinically defined cutoff points for 
the numbers of VASH1, VEGF-A, CD34, VEGF-C and 
D2-40 in the tumor tissues, the median expression of each 
molecule (4.2 for stroma VASH1; 2.6 for paracancerous 
tissue VASH1; 29 for CD34; and 12.4 for D2-40) in colon 
cancer tissues was used as a cutoff point to define the 
high and low expression groups (in tables). Fisher and 
Pearson’s Chi-square tests were used to prospectively 
analyze the correlations between the expression levels of 
each marker and clinical features, including gender, age, 
pathologic types, clinical stages, tumor differentiation, 
lymph node metastases, other organs metastases, relapse-
free survival (RFS), and overall survival (OS). OS was 
determined from the date of surgery to the date of death 
by any cause or to the date of the last follow-up. RFS 
was measured as the length of time from surgery to the 
date of relapse. Data processing and statistical analyses 
were performed using SAS 9.1 and R 2.13.0. Statistical 
significance was defined when alpha <0.05 (2-tailed). For 
other studies shown in figures, unless indicated otherwise, 
data are expressed as mean ± standard deviation (SD). The 
significance of difference between groups was determined 
by a two-tailed Student’s t-test or the one-way analysis of 
variance (ANOVA).
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